Skip to main content

DYSPORT (Ispen Pty Ltd)

Product name
DYSPORT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 working days (255)
Active ingredients
clostridium botulinum type A toxin - haemagglutinin complex
Registration type
EOI
Indication

DYSPORT is now also indicated for the symptomatic treatment of:

  • focal spasticity affecting the upper limbs in adults.
  • focal spasticity affecting the lower limb in adults.
  • lower limb focal spasticity in children aged 2 years of age or older.

Help us improve the Therapeutic Goods Administration site